FAVC化疗方案对原位宫颈癌患者免疫功能的影响研究

Study on effects of FAVC chemotherapy on immune function of patients with cervical carcinoma in situ

目的观察FAVC化疗方案对原位宫颈癌患者免疫功能的影响。方法选取本科诊治的初治原位宫颈癌患者35例为研究对象,采用5氟脲嘧啶+阿霉素+长春新碱+环磷酰胺方案化疗。测定和比较治疗前及治疗2周期后CD4+、CD8+、CD4+/CD8+、Ig G、Ig M、Ig A及调节性T细胞/CD4+及淋巴细胞计数。结果治疗前后比较,CD4+、CD8+及CD4+/CD8+和免疫球蛋白Ig G、Ig M、Ig A均无显著变化(P>0.05)。与治疗前比较,治疗后调节性T细胞/CD4+显著升高,淋巴细胞计数显著降低(P<0.05)。结论在原位宫颈癌患者的治疗中,FAVC化疗方案会造成淋巴细胞计数降低,调节性T细胞/CD4+显著升高。

Objective To observe the effects of FAVC chemotherapy on immune function of patients with cervical carcinoma in situ. Methods A total of 35 patients admitted to our department for early treatment of cervical carcinoma in situ were selected and treated with 5-fluorouracil ＋ doxorubicin ＋ VCR ＋ cyclophosphamide chemotherapy. The CD4＋, CD8＋, CD4＋/CD8＋, Ig G, Ig M, Ig A and regulatory T cell/CD4 and lymphocyte count before the treatment and after two cycles of treatment were determined and compared.Results The CD4＋, CD8＋, CD4＋/CD8＋, Ig G, Ig M and Ig A before and after the treatment had no significant difference（P〈0.05）. The regulatory T cell/CD4 was much higher than and lymphocyte count much lower than that before the treatment（P〈0.05）. Conclusion FAVC chemotherapy may lower the lymphocyte count and significantly increase regulatory T cell/CD4 in the treatment of cervical carcinoma in situ.